Eli Lilly Still Pursuing EUA For Antibody Amid Trial Pause, Investigation

By Beth Wang / October 15, 2020 at 5:31 PM
Eli Lilly is still pursuing emergency use authorization for its COVID-19 antibody therapy, LY-CoV555 (bamlanivimab), for use in mild-to-moderate COVID-19 patients, even as its National Institutes of Health-sponsored trial of hospitalized patients remains on hold while an independent group of experts reviews the trial data, a company spokesperson confirmed to Inside Health Policy . “In seeking an emergency use application, we fully expect the FDA will hold us to the same high quality standards to which it holds all applicants,”...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.